AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

August 11, 2017: By Jon Swedien

AGTCApplied Genetic Technologies Corporation announced Aug. 10 that it has filed an investigational new drug application (IND) with the US FDA to conduct a Phase I/II clinical trial for the company’s gene therapy candidate for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

AGTC said it plans to start the study in the US in the coming months.

AGTC is currently scheduling patients for enrollment in clinical trials for X-linked retinoschisis (XLRS), as well as for achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, the Alachua, Florida, company said.

On Aug. 3, AGTC announced that the FDA granted orphan drug designation to the XLRP gene therapy candidate. The European Commission granted orphan medicinal product designation for the same indication in 2016.

XLRP is an inherited condition that causes progressive vision loss.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023